Court approval has been granted for a national Settlement Agreement that settles all litigation and claims in Canada relating to Fosamax and Fosavance. The deadline to file a claim is July 17, 2017.
Class proceeding lawsuits had been initiated in several provinces in relation to the ingestion and/or purchase of Fosamax and Fosavance. Fosamax is a prescription medication for the treatment and prevention of osteoporosis. Fosavance is a prescription medication for the treatment of osteoporosis.
Under the settlement approved by the courts, claimants or their estates may be eligible to receive settlement payments if they took Fosamax and/or Fosavance and then experienced osteonecrosis of the jaw (“ONJ”) or an atypical femur fracture ("AFF").